ClinicalTrials.gg
Not yet recruitingNCT06644469Updated Oct 18, 2024

Whole Body Vibration in Middle Aged Men

An interventional study of Dynatronics VF5 Model vibration platform and Placebo Dynatronics VF5 Model vibration platform in Bone Density and Muscle Weakness, sponsored by Jouf University. Not yet recruiting at 1 site in Saudi Arabia. Open to male participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Jouf University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Study summary

This study aims of this clinical trial is to evaluate the effect of an 8-week Whole Body Vibration (WBV) intervention on Bone Mineral Density (BMD), hand grip strength, and vitamin D levels in middle-aged men. Findings from this study will contribute to understanding whether WBV is a viable alternative to conventional exercise, especially for those with limitations in physical activity.

Study Objectives:

  • Primary Objective: To assess the effectiveness of an 8-week WBV intervention in improving BMD, hand grip strength, and vitamin D levels compared to a placebo intervention.
02

Conditions studied

  • Bone Density
  • Muscle Weakness

Browse trials for

Keywords

  • Pilot Study
  • Bone Density
  • Vibration Therapy
  • Vitamin D
  • Muscle Strength
03

In context

Muscle Weakness

478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.

This study's planned enrollment of 34 is below the median of 44 across 364 interventional studies indexed under Muscle Weakness.

Browse Muscle Weakness studies →

Lead sponsor

Jouf University is the lead sponsor of 22 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants aged 50 years or older
  • Participants with physical activity or exercise program involvement
  • Participants with no history of serious medical conditions such as tumors, fractures, epilepsy, cardiac disease, or stroke within the past year.
  • Participants must be non-smokers and not receiving hormone or calcium supplement therapy

Exclusion criteria

Exclusion Criteria:

  • Participants unable to stand on the WBV platform
  • Participants with conditions contraindicating vibration therapy
  • Participants participating in other clinical trials
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (estimated)

Study arms

  • Placebo comparator
    Control Group with placebo vibration therapy

    Participants will perform the same activities as the experimental group, but with a vertical displacement of 0.22 mm, deemed therapeutically insufficient.

    Device: Placebo Dynatronics VF5 Model vibration platform

  • Experimental
    Experimental Group

    Participants will undergo an 8-week WBV therapy program using a Dynatronics VF5 Model vibration platform. Each session will last 4 minutes, with vibration frequencies progressively increased from 25 Hz to 40 Hz without rest intervals.

    Device: Dynatronics VF5 Model vibration platform

Interventions

  • DeviceDynatronics VF5 Model vibration platform

    The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.

  • DevicePlacebo Dynatronics VF5 Model vibration platform

    Placebo intensity with vertical vibration of 0.2 mm

06

What researchers measure

Primary outcomes

  1. Bone Density

    Changes in BMD (measured by DXA scanner),

    Time frame: 8 weeks

  2. Grip Strength

    hand grip strength (measured by a hand-held dynamometer)

    Time frame: 8 weeks

  3. Vitamin D

    Vitamin D levels (measured by high-performance liquid chromatography).

    Time frame: 8 weeks

07

Study locations

1 site
  • prince Mutaib bin Abdulaziz hospital
    Sakaka, Aljouf 77634, Saudi Arabia
    • Khalid Alrwaily Mr, BPT · ContactK.Alrwaily@moh.edu.sa · +966543944811
    • Fahad Alanazi Dr Assitant professor, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Dec 2024, 1 month later.

Of 200 non-industry interventional studies with no phase under Muscle Weakness, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 1 month is below that.

Counting every sponsor, half of 212 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartEst.
Oct 15, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 15, 2024
Last update
Oct 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644469
Lead sponsor
Jouf University
Responsible party
Fahad Alanazi (Assistant professor, Jouf University) — Principal investigator
First posted
Oct 16, 2024
Start date
Oct 15, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Oct 18, 2024

Study contacts

Fahad Alanazi, PhD
Contact
Fsalenezi@ju.edu.sa
00966503409217
Fahad Alanazi, PhD
principal investigator · Jouf University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion